2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139788A
    Fesomersen sodium 2380288-85-5 98.67%
    Fesomersen (sodium) is an antisense oligonucleotide designed to inhibit the production of Factor XI.
    Fesomersen sodium
  • HY-145564A
    Emprumapimod hydrochloride 98.0%
    Emprumapimod (PF-07265803) hydrochloride is an orally active and selective inhibitor of p38α MAPK. Emprumapimod hydrochloride can be used for the research of dilated cardiomyopathy and acute inflammatory pain.
    Emprumapimod hydrochloride
  • HY-148144A
    Clobutinol hydrochloride 1215-83-4 99.86%
    Clobutinol hydrochloride is a compound that has anti-tussive effects. Clobutinol hydrochloride affects heart rate and blood pressure, it can be used for cough related research.
    Clobutinol hydrochloride
  • HY-14870S1
    Selexipag-d7 1265295-21-3 98.44%
    Selexipag-d7 is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).
    Selexipag-d7
  • HY-152106A
    (+)-BAY-7081 99.21%
    (+)-BAY-7081 is an optical isomer of BAY-7081 (HY-152106). BAY-7081 is a potent, selective, orally active and soluble cyanopyridone-based PDE9A inhibitor with an IC50 of 15 nM.
    (+)-BAY-7081
  • HY-152106B
    (±)-BAY-7081 99.06%
    (±)-BAY-7081 is a racemate of BAY-7081 (HY-152106). BAY-7081 is a potent, selective, orally active and soluble cyanopyridone-based PDE9A inhibitor with an IC50 of 15 nM.
    (±)-BAY-7081
  • HY-15284S1
    Prasugrel-d3 1127253-02-4 98.58%
    Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel-d3
  • HY-156794A
    Enzomenib enantiomer 98.01%
    Enzomenib enantiomer (DSP-5336 enantiomer) is an enantiomer of Enzomenib (HY-156794). Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations.
    Enzomenib enantiomer
  • HY-159002S
    Methyl-warfarin-d3 99.95%
    Methyl-warfarin-d3 is a deuterated labeling methylated Warfarin (HY-B0687).
    Methyl-warfarin-d3
  • HY-17376S1
    Ezetimibe-d4-1 1093659-89-2 99.26%
    Ezetimibe-d4-1 is deuterium labeled Ezetimibe. Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
    Ezetimibe-d4-1
  • HY-175742A
    (R)-BMS-986470 99.93%
    (R)-BMS-986470 is the enantiomer of BMS-986470 (HY-175742). BMS-986470, a HbF-activating CRBN E3 ligase modulator (CELMoD), is an orally active dual molecular glue degrader targeting ZBTB7A and WIZ.
    (R)-BMS-986470
  • HY-177247A
    Mitotic kinesin-IN-2 hydrochloride
    Mitotic kinesin-IN-2 (Page 135, fifteenth) hydrochloride is a Mitotic kinesin inhibitor. Mitotic kinesin-IN-2 hydrochloride inhibits cell proliferation by suppressing mitosis. Mitotic kinesin-IN-2 hydrochloride can be used for cancer, cardiac hypertrophy, immune and inflammatory disorders, fungal infections research.
    Mitotic kinesin-IN-2 hydrochloride
  • HY-177248A
    Mitotic kinesin-IN-3 hydrochloride
    Mitotic kinesin-IN-3 (Page 135, fourteenth) hydrochloride is a Mitotic kinesin inhibitor. Mitotic kinesin-IN-3 hydrochloride inhibits cell proliferation by suppressing mitosis. Mitotic kinesin-IN-3 hydrochloride can be used for cancer, cardiac hypertrophy, immune and inflammatory disorders, fungal infections research.
    Mitotic kinesin-IN-3 hydrochloride
  • HY-178049A
    UM-259 hydrochloride
    UM-259 hydrochloride is a STING inhibitor with activity against both murine and human STING (including the STINGR232 mutant). UM-259 hydrochloride inhibits STING-dependent signaling pathways, blocks STING oligomerization, and acts on human primary CD14+ monocytes. UM-259 hydrochloride can be used for research on amyotrophic lateral sclerosis, lupus erythematosus, Aicardi-Goutières syndrome, and infant-onset STING-associated vasculopathy.
    UM-259 hydrochloride
  • HY-182095A
    DSPE-PEG2000-CTP
    DSPE-PEG2000-CTP is a PEG compound which composed of DSPE and a Cardiac-targeting peptide CTP (HY-P4094). CTP molecules that specifically recognize cardiac tissue and is primarily used for targeted drug delivery. CTP effectively recognizes and binds to specific receptors on the surface of cardiac cells, thereby achieving precise localization of drug molecules. DSPE-PEG2000-CTP can be used for drug delivery.
    DSPE-PEG2000-CTP
  • HY-79593S1
    MRE-269-d6 1265295-56-4 98%
    MRE-269-d6 is deuterium labeled MRE-269. MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
    MRE-269-d6
  • HY-B0205S1
    Candesartan-d5 1189650-58-5
    Candesartan-d5 is the deuterium labeled Candesartan. Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
    Candesartan-d5
  • HY-B0231BS
    Enalaprilat-d5 sodium 1356922-29-6 98.0%
    Enalaprilat-d5 (sodium) is the deuterium labeled Enalaprilat(MK-422), which is an angiotensin-converting enzyme (ACE) inhibitor.
    Enalaprilat-d5 sodium
  • HY-B0252S1
    Hydrochlorothiazid-13C,d2 1190006-03-1 98.64%
    Hydrochlorothiazid-13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.
    Hydrochlorothiazid-13C,d2
  • HY-B0317BR
    Amlodipine besylate (Standard) 111470-99-6 99.98%
    Amlodipine (besylate) (Standard) is the analytical standard of Amlodipine (besylate). This product is intended for research and analytical applications. Amlodipine besylate (Amlodipine benzenesulfonate), an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine besylate can be used for the research of high blood pressure and cancer.
    Amlodipine besylate (Standard)
Cat. No. Product Name / Synonyms Application Reactivity